Arrivent Biopharma Inc
AVBP21.970USD
-0.320-1.44%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
897.53MMarket Cap
LossP/E TTM
More Details of Arrivent Biopharma Inc Company
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Company is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.
Arrivent Biopharma Inc Info
Ticker SymbolAVBP
Company nameArriVent BioPharma Inc
IPO dateJan 26, 2024
CEOYao (Zhengbin)
Number of employees52
Security typeOrdinary Share
Fiscal year-endJan 26
Address18 Campus Blvd.
CityNEWTOWN SQUARE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19073-3269
Phone12407806356
Websitehttps://arrivent.com/
Ticker SymbolAVBP
IPO dateJan 26, 2024
CEOYao (Zhengbin)
Company Executives of Arrivent Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Robin Lachapelle
Ms. Robin Lachapelle
Chief Operating Officer
Chief Operating Officer
530.21K
+2.15%
Dr. James I. Healey, M.D., Ph.D.
Dr. James I. Healey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Stuart Lutzker, M.D., Ph.D.
Dr. Stuart Lutzker, M.D., Ph.D.
Director, President of Research and Development
Director, President of Research and Development
--
--
Mr. James Kastenmayer, J.D., Ph.D.
Mr. James Kastenmayer, J.D., Ph.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Winston W. Kung
Mr. Winston W. Kung
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Mr. Chris W. Nolet
Mr. Chris W. Nolet
Independent Director
Independent Director
--
--
Dr. Zhengbin (Bing) Yao, Ph.D.
Dr. Zhengbin (Bing) Yao, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Lead Independent Director
Lead Independent Director
--
--
Dr. Merdad V. Parsey, M.D., Ph.D.
Dr. Merdad V. Parsey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Robin Lachapelle
Ms. Robin Lachapelle
Chief Operating Officer
Chief Operating Officer
530.21K
+2.15%
Dr. James I. Healey, M.D., Ph.D.
Dr. James I. Healey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Stuart Lutzker, M.D., Ph.D.
Dr. Stuart Lutzker, M.D., Ph.D.
Director, President of Research and Development
Director, President of Research and Development
--
--
Mr. James Kastenmayer, J.D., Ph.D.
Mr. James Kastenmayer, J.D., Ph.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Winston W. Kung
Mr. Winston W. Kung
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
HHLR Advisors, Ltd.
10.86%
INFINITUM ASSET MANAGEMENT, LLC
9.37%
Suvretta Capital Management, LLC
8.97%
Fidelity Management & Research Company LLC
8.25%
OrbiMed Advisors, LLC
7.33%
Other
55.21%
Shareholders
Shareholders
Proportion
HHLR Advisors, Ltd.
10.86%
INFINITUM ASSET MANAGEMENT, LLC
9.37%
Suvretta Capital Management, LLC
8.97%
Fidelity Management & Research Company LLC
8.25%
OrbiMed Advisors, LLC
7.33%
Other
55.21%
Shareholder Types
Shareholders
Proportion
Investment Advisor
39.54%
Investment Advisor/Hedge Fund
18.55%
Hedge Fund
17.79%
Venture Capital
12.44%
Private Equity
7.33%
Individual Investor
3.13%
Research Firm
2.20%
Family Office
1.02%
Bank and Trust
0.16%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
203
40.51M
86.20%
+2.23M
2025Q3
200
38.29M
87.13%
+4.89M
2025Q2
183
33.29M
86.81%
+2.78M
2025Q1
161
29.16M
89.66%
-1.36M
2024Q4
146
28.54M
81.09%
+2.38M
2024Q3
112
25.96M
67.99%
+4.20M
2024Q2
92
21.76M
65.52%
-193.40K
2024Q1
72
21.95M
14.98%
+16.93M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
HHLR Advisors, Ltd.
4.48M
11.05%
--
--
Jun 30, 2025
INFINITUM ASSET MANAGEMENT, LLC
3.42M
8.43%
--
--
Jun 30, 2025
Suvretta Capital Management, LLC
3.41M
8.41%
+1.08M
+46.00%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.06M
5.07%
-20.59K
-0.99%
Jun 30, 2025
OrbiMed Advisors, LLC
3.03M
7.46%
--
--
Aug 13, 2025
The Vanguard Group, Inc.
1.48M
3.65%
-19.82K
-1.32%
Jun 30, 2025
Octagon Capital Advisors LP
1.95M
4.8%
-113.33K
-5.50%
Jun 30, 2025
Novo Holdings A/S
1.87M
4.61%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.66M
4.09%
-294.70K
-15.08%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.54%
State Street SPDR S&P Biotech ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.11%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Biotechnology ETF
0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
Global X Russell 2000 ETF
0.02%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.54%
State Street SPDR S&P Biotech ETF
Proportion0.16%
ProShares Ultra Nasdaq Biotechnology
Proportion0.11%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.1%
iShares Micro-Cap ETF
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%
iShares Biotechnology ETF
Proportion0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0.05%
iShares Russell 2000 Growth ETF
Proportion0.03%
Global X Russell 2000 ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Arrivent Biopharma Inc?
The top five shareholders of Arrivent Biopharma Inc are:
HHLR Advisors, Ltd. holds 4.48M shares, accounting for 11.05% of the total shares.
INFINITUM ASSET MANAGEMENT, LLC holds 3.42M shares, accounting for 8.43% of the total shares.
Suvretta Capital Management, LLC holds 3.41M shares, accounting for 8.41% of the total shares.
Fidelity Management & Research Company LLC holds 2.06M shares, accounting for 5.07% of the total shares.
OrbiMed Advisors, LLC holds 3.03M shares, accounting for 7.46% of the total shares.
HHLR Advisors, Ltd. holds 4.48M shares, accounting for 11.05% of the total shares.
INFINITUM ASSET MANAGEMENT, LLC holds 3.42M shares, accounting for 8.43% of the total shares.
Suvretta Capital Management, LLC holds 3.41M shares, accounting for 8.41% of the total shares.
Fidelity Management & Research Company LLC holds 2.06M shares, accounting for 5.07% of the total shares.
OrbiMed Advisors, LLC holds 3.03M shares, accounting for 7.46% of the total shares.
What are the top three shareholder types of Arrivent Biopharma Inc?
The top three shareholder types of Arrivent Biopharma Inc are:
HHLR Advisors, Ltd.
INFINITUM ASSET MANAGEMENT, LLC
Suvretta Capital Management, LLC
HHLR Advisors, Ltd.
INFINITUM ASSET MANAGEMENT, LLC
Suvretta Capital Management, LLC
How many institutions hold shares of Arrivent Biopharma Inc (AVBP)?
As of 2025Q4, 203 institutions hold shares of Arrivent Biopharma Inc, with a combined market value of approximately 40.51M, accounting for 86.20% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.93%.
What is the biggest source of revenue for Arrivent Biopharma Inc?
In --, the -- business generated the highest revenue for Arrivent Biopharma Inc, amounting to -- and accounting for --% of total revenue.
